Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
Ascentage Pharma reported unaudited 2025 results, showing product sales surged 90% to $82.1 million while total revenue fell 41.5% after a $92.9 million drop in intellectual‑property income. Olverembatinib generated $62.2 million, up 81% YoY, and the newly launched Lisaftoclax contributed $10.1 million in its first five months. The company is running nine registrational Phase III trials, four of which have FDA and EMA clearance, and its cash balance rose to $353.2 million following a U.S. IPO and a follow‑on offering.
Press Release - Fiscal-Year 2025 Results: AFL Group Delivers Record Results, Doubling Its Net Profit
AFL Group posted record fiscal‑year 2025 results, doubling net profit to €10.8 million (about $11.9 million) and lifting net banking income 28% to €30.8 million ($33.9 million). The bank’s gross operating income surged 70% to €13.3 million, while its CET1 capital ratio climbed to 59.45%...
JBS Reports Record Revenue of US$ 86.2 Billion and Closes 2025 with US$ 2 Billion in Net Income
JBS announced record full‑year 2025 revenue of $86.2 billion, a 12% increase over 2024, and net income of $2 billion, up 13%. Earnings per share rose 15% to $1.89, while adjusted EBITDA reached $6.8 billion with a 7.9% margin. Strong contributions came from...
17 Education & Technology Group Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results
17 Education & Technology Group Inc. reported Q4 2025 revenue of RMB 38.9 million ($5.6 million), a 6% year‑over‑year increase, while full‑year revenue dropped 44% to RMB 106.0 million ($15.2 million). Gross margins rose to 46.1% in Q4 and 47.8% for the year, reflecting a shift...
Erdene Announces 2025 Results - Provides Bayan Khundii Gold Mine and Exploration Update
Erdene Resource Development completed construction of the high‑grade Bayan Khundii Gold Mine in Q3 2025 and began production in September, selling 7,434 oz of gold at a weighted‑average $4,187 per ounce, generating roughly $31 million in gross revenue. The mill operates near its 85,000‑oz...
Skeena Reports Fourth Quarter and Annual 2025 Financial Results
Skeena Resources Limited released its fourth‑quarter and full‑year 2025 financial results, reaffirming that the Eskay Creek gold‑silver project in British Columbia is fully permitted and now under construction. The company targets initial production and positive cash flow in the second...
Epsilon Announces Full Year 2025 Results
Epsilon Energy reported full‑year 2025 results, posting $51.6 billion in total revenue, a 64% year‑over‑year increase. Adjusted EBITDA surged 75% to $30.7 billion and adjusted net income rose to $21.3 billion, while cash and short‑term investments grew 36% to $9.5 billion. Production jumped sharply,...
Glass House Brands Reports Fourth Quarter and Full Year 2025 Financial Results
Glass House Brands reported fourth‑quarter 2025 revenue of $38.9 million, in line with guidance but down from $53 million a year earlier, while full‑year 2025 revenue fell 9% to $182 million. Adjusted EBITDA turned positive at $17 million for the year, yet operating cash...
Comstock Announces Full Year 2025 Achievements and Results
Comstock Inc. reported full‑year 2025 results and outlined an aggressive 2026 outlook, highlighted by a $57.5 million equity raise that eliminated all debt and boosted cash to $56.1 million. The company secured permits for its first industry‑scale solar‑panel recycling plant in Nevada...
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation announced that its AI‑designed antibody ABS‑201 has been dosed in the first three single‑ascending‑dose cohorts of the Phase 1/2a HEADLINE trial, showing favorable safety and early hair‑growth signals in human ex vivo studies. The company also unveiled Origin‑1, a generative‑AI...
Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights
Biomea Fusion announced its FY 2025 results, reporting $56.2 million in cash and a net loss of $61.8 million, roughly half the loss recorded a year earlier. The company highlighted durable 52‑week HbA1c reductions of 1.2 % from icovamenib in type 2 diabetes and launched...
HomesToLife Delivers 97% Jump in FY2025 Net Profit to US$16.6 Million
HomesToLife Ltd reported FY2025 net profit of $16.6 million, a 97% jump from the prior year, driven by a 13% rise in net revenue to $377.9 million. Export sales grew 12% to $349.6 million, with Europe and North America leading the expansion, while...
Kandal M Venture Limited Announces Financial Results for the Six Months Ended September 30, 2025
Kandal M Venture Limited reported a 17% revenue decline to $7.9 million for the six months ended September 30 2025, driven primarily by higher U.S. import tariffs and related discounts. Gross profit fell 34.7% and margin slipped to 18.7% as material and labor...
Conifex Announces 2025 Year-End and Fourth Quarter Results
Conifex Timber Inc. posted a 2025 full‑year loss of $35.7 million, with EBITDA of negative $27.5 million, widening the deficit from the prior year. Revenue rose 7% to $101 million, but higher softwood lumber duties and a 10% Section 232 tariff pushed duty costs...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Xilio Therapeutics reported a strong cash position of $137.5 million, extending its runway to the end of 2027, and highlighted significant pipeline advances. The company plans to file an IND for its bispecific PD‑1/masked IL‑2 candidate XTX501 in mid‑2026 and start...
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio announced its Q4 and full‑year 2025 results, highlighting a surge in R&D spending to $142.7 million and a cash balance of $133.6 million. The company is advancing its CAR‑T cell therapy rese‑cel, with a registrational BLA for myositis slated for...
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Arbutus Biopharma announced a $950 million upfront settlement from Moderna, with a potential $1.3 billion contingent payment, strengthening its cash position to $91.5 million. The company reported $14.1 million revenue for 2025, driven by license milestones, while cutting R&D expenses by $28.8 million. Clinical progress...
WeRide Reports Record Full Year 2025 Revenue of RMB684.6 Million, Up 90% Year over Year
WeRide announced full‑year 2025 revenue of $97.9 million, a 90% increase year‑over‑year, driven by a 310% surge in product sales and a 210% jump in robotaxi revenue. The company’s robotaxi fleet expanded to 1,125 vehicles operating in 12 countries, while gross...
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Pyxis Oncology announced completion of target enrollment for its Phase 1 MICVO monotherapy study in recurrent/metastatic head and neck cancer, enrolling roughly 40 patients. Interim CEO Thomas Civik highlighted promising early efficacy, with a 46% objective response rate as monotherapy and a...
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
Avalo Therapeutics announced its 2025 financial results, reporting $98.3 million in cash and short‑term investments that should fund operations into 2028. Research and development expenses jumped to $50.1 million, driven by the Phase 2 LOTUS trial of abdakibart (AVTX‑009) for hidradenitis suppurativa. The...
H Group Plc’s Financial Statements Release for 1 January – 31 December 2025: A Strong End to 2025
KH Group Plc reported 2025 net sales of €204.5 million, a 5% increase year‑on‑year, while comparable operating profit slipped 11% to €6.4 million. Net profit fell to €1.0 million and earnings per share declined to €0.01. The balance sheet showed a marked reduction...
2025 ANNUAL RESULTS - Transdev Group in 2025: Solid Growth, Enhanced Visibility, and Financial Strength
Transdev reported 2025 results showing solid growth, with revenue reaching €10.44 bn (+4%) and adjusted EBITDA rising 5% to €691 m. Operating investments increased 9% to €691 m, supporting vehicle electrification and heavy‑mode expansions such as the Marseille‑Nice rail line and the Cable C1...
LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
LexinFintech Holdings reported unaudited results for Q4 and full‑year 2025, posting a net profit of RMB 1.7 billion—a 52.4% year‑over‑year increase—despite a 7.4% decline in total operating revenue to RMB 13.2 billion. The company’s loan‑originations fell modestly, while outstanding loan balances dropped 12.4%, reflecting...
Bakkt Releases Shareholder Letter and Reports Full Year 2025 Financial Results
Bakkt released a shareholder letter and FY2025 results, outlining a year of extensive restructuring and a strategic shift toward a unified digital‑finance platform. The company eliminated debt, raised about $100 million, and divested non‑core custody and loyalty businesses to simplify its...
Consolidated Water Reports Full Year 2025 Results
Consolidated Water Co. Ltd. posted 2025 results showing a modest 1% decline in total revenue to $132.1 million, while net income from continuing operations rose 4% to $18.6 million ($1.16 per share). Retail revenue grew 6% driven by record water sales in...
Microvast Reports 2025 Financial Results
Microvast reported FY 2025 revenue of $427.5 million, up 12.6% year‑over‑year but below its guidance. Gross margin slipped to 28.6% after a $32.5 million inventory impairment, while operating expenses were cut by half. The company posted a GAAP net loss of $29.2 million, yet...
Dragonfly Energy Announces Significant Corporate Actions and Reports Fourth Quarter and Full Year 2025 Preliminary Results
Dragonfly Energy reported a 16% increase in full‑year 2025 revenue to $58.6 million, driven by a 34% jump in OEM sales. The company posted a net loss of $69.9 million for the year but expects adjusted EBITDA to improve as it implements...
Natural Gas Services Group, Inc. Reports Fourth Quarter and Full Year 2025 Financial and Operating Results; Provides 2026 Guidance
Natural Gas Services Group reported record financial results for 2025, with rental revenue rising 13.9% year‑over‑year to $164.3 million and full‑year adjusted EBITDA climbing 16.5% to $81.0 million. Net income reached $19.9 million, and fleet utilization hit a historic 84.9% as rented horsepower...
Greystone Housing Impact Investors Reports Fourth Quarter 2025 Financial Results
Greystone Housing Impact Investors LP reported a Q4 2025 net loss of $2.6 million and cash available for distribution (CAD) of $2.8 million, while the full‑year results showed a $7.6 million loss and $19.1 million CAD. The partnership holds $1.5 billion in assets, with $1.15 billion...
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results
Perspective Therapeutics released its full‑year 2025 results, highlighting robust interim data from its lead alpha‑emitting radiopharmaceutical VMT‑α‑NET in neuroendocrine tumors. The study reported a 76% progression‑free rate at 48 weeks and no dose‑limiting toxicities across three dose cohorts. The company...
Security National Financial Corporation Reports Financial Results for the Year Ended December 31, 2025
Security National Financial Corporation reported a strong 2025 fiscal year, with after‑tax earnings from operations climbing 10.8% to $32.2 million and revenue rising 3% to $344.6 million. The Life Insurance segment delivered its best operational year, posting a 5.1% revenue increase and...
Urgently Announces Fourth Quarter 2025 Financial Results
Urgently Inc. posted Q4 2025 revenue of $33.3 million, up 4% year‑over‑year, and lifted gross margin to 26%, a four‑point improvement. GAAP operating loss narrowed 46% to $2.5 million, while non‑GAAP operating income turned positive at $0.2 million, a 106% swing. For the full...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals announced FDA approval and U.S. launch of TONMYA, the first new fibromyalgia drug in over 15 years, in August 2025 with commercial availability beginning November 17, 2025. The company reported fourth‑quarter product revenue of $5.4 million and full‑year revenue...
Imperial Reports 2025 Financial Results
Imperial Metals posted record 2025 revenue of $691.8 million, a 40% increase year‑over‑year, driven by higher copper and gold prices and strong output at Mount Polley and Red Chris. Adjusted EBITDA rose to $381.7 million and net income reached $153.8 million, while cash cost per...
Swiss Water Reports Year End and Fourth Quarter 2025 Results
Swiss Water Decaffeinated Coffee reported a strong top line in 2025, with revenue climbing 49% to C$258.7 million and Q4 revenue up 34% to C$66.0 million. Net income rose 23% year‑over‑year to C$1.6 million, though Q4 profit fell 40% due to lower volumes...
Legacy Housing Corporation Reports Full Year 2025 Financial Results
Legacy Housing Corporation reported a 10.7% drop in 2025 revenue to $164.6 million and a 32.2% decline in net income to $41.8 million. Despite weaker earnings, book value per share rose 8.6% to $22.20, and the company generated $37.2 million of operating cash....
VAALCO Energy, Inc. Announces Fourth Quarter and Full Year 2025 Results
Vaalco Energy reported FY 2025 results with net sales of 6,370 MBOE and a net loss of $41.4 million, while generating $173.4 million of Adjusted EBITDAX and $212.7 million of operating cash. Production averaged 16,556 NRI BOEPD, surpassing guidance, and the company sold 17,452 NRI BOEPD. It secured a...
AMREP Reports Third Quarter Fiscal 2026 Results
AMREP Corporation posted a strong third‑quarter fiscal 2026, reporting $14.6 million in revenue and $3.15 million net income, up from $7.5 million and $0.72 million a year earlier. Earnings per diluted share rose to $0.58 from $0.13, while nine‑month revenue reached $41.8 million and net...
Atlanticus Reports Fourth Quarter 2025 Financial Results
Atlanticus Holdings reported a blockbuster fourth‑quarter 2025, posting $734.4 million in total operating revenue—a 108% year‑over‑year jump—and $7.0 billion in managed receivables, up 155%. Net income rose 24.9% to $32.8 million, delivering $1.75 diluted earnings per share. The results were powered by the...
Artesian Resources Corporation Reports 2025 Year-End Earnings and Fourth Quarter Results
Artesian Resources Corp reported full‑year 2025 results, posting net income of $22.8 million, an 11.9% increase year‑over‑year, and diluted earnings per share of $2.21, up 11.6%. Total revenues rose 4.6% to $112.9 million, driven by modest gains in water sales, wastewater, and...
JOYY Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results
JOYY Inc. posted unaudited Q4 2025 results showing net revenues of $581.9 million, a 5.9% year‑over‑year increase, and a full‑year 2025 revenue of $2.124 billion. Advertising revenue surged 62.4% YoY to $145.4 million, driven by the AI‑powered BIGO Ads platform, while operating income...
Firm Capital Property Trust Reports Q4/2025 and YTD Results
Firm Capital Property Trust (TSX:FCD.UN) posted a strong Q4 2025, with net income jumping 118% to $12.5 million and AFFO per unit rising 2% to $0.133. The Trust’s portfolio now includes 62 commercial assets, 599 multi‑residential units and 537 manufactured‑home units, with...
FLINT Announces Fourth Quarter and 2025 Annual Financial Results
FLINT Corp. posted 2025 revenues of C$563.8 million, a 20.6% decline driven by delayed construction and market softness. Adjusted EBITDAS fell 13.8% to C$30.6 million, yet margins improved to 5.4% as the work mix shifted. A September recapitalization eliminated senior debt, consolidated...
Arq Reports Fourth Quarter and Full Year 2025 Results
Arq Inc. reported FY2025 revenue of $120.3 million, a 10 % increase year‑over‑year, driven by record powdered activated carbon (PAC) sales. Gross margins fell to 27.9 % as the company incurred a $45 million non‑cash impairment and higher costs from its granular activated carbon...
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
SAB Biotherapeutics announced full‑year 2025 results, highlighting the launch of its registrational Phase 2b SAFEGUARD trial for SAB‑142 and the completion of a $175 million oversubscribed private placement. Phase 1 data demonstrated a favorable safety profile, no serum sickness and low immunogenicity across...
Alaris Releases 2025 Fourth Quarter Financial Results
Alaris Equity Partners Income Trust posted a strong fourth‑quarter 2025, with total revenue and operating income rising 15.9% and 34.8% respectively, driven by a $73.2 million unrealized gain on partner investments. Net book value per unit climbed to $24.79, while the...
Flagship Communities Real Estate Investment Trust Announces Fourth Quarter and Full Year 2025 Results
Flagship Communities Real Estate Investment Trust reported strong fourth‑quarter and full‑year 2025 results, with rental revenue climbing 17% to $103.4 million and net income rising 12% to $115.7 million. NOI increased 17% year‑over‑year to $68.4 million, while FFO per unit grew 12% and...
NL REPORTS FOURTH QUARTER 2025 RESULTS
NL Industries reported a Q4 2025 net loss of $31 million, or $0.63 per share, reversing a $16.5 million profit a year earlier. The full‑year 2025 results showed a $37.8 million loss, compared with $67.2 million earnings in 2024. Losses were driven by a...
KRONOS WORLDWIDE, INC. REPORTS FOURTH QUARTER 2025 RESULTS
Kronos Worldwide reported a Q4 2025 net loss of $82.8 million, or $0.72 per share, widening sharply from a $13.2 million loss a year earlier. For the full year, the company posted a $110.9 million loss, reversing the $86.2 million profit recorded in 2024....
Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update
Coherus Oncology posted FY 2025 revenue of $42.2 million, driven by a 64% year‑over‑year jump in LOQTORZI sales and a $12.4 million Q4 boost. The company cut its debt by more than 90% to $38.8 million and lifted cash reserves to $172.1 million after two...
